With the kinase inhibitor field developing rapidly, novel applications beyond oncology are in hot pursuit. This conference will present developments in areas such as CNS, pain, anti-inflammatories, cardiotoxicity, diabetes and more.
In additionm, prioritizing targets has become extremely important and optimized validation and screening technologies are needed to keep up with the current pace. Key issues such as developing lead compounds, integrating chemistry and biology, using promising techniques such as fragment and structure based design as well as optimizing PK and PD and how to analyze the flood of data available will be addressed in this conference.
Take advantage of the opportunity to learn and discuss state-of-the-art projects in novel and promising areas in the field of kinase inhibitors.
Distinguished Faculty
Inhibition of Kinases by Deuterated Imidazole Compounds
Colin Kenyon, Group Leader, Biosciences, CSIR
Talk Title to be Announced
Kenneth Thress, Ph.D., Principal Scientist, Cancer and Infection Research, AstraZeneca
Talk Title to be Announced
Juswinder Singh ,Ph.D., Founder and CSO, Avila Therapeutics, Inc.
In Silico Structure Based Design of Non-ATP Competitive Kinase Inhibitors
Thomas Chan, CSO, ArQule, Inc.
Allosteric Kinase Inhibitors: Opportunities Beyond the Kinase Domain
Jeffrey Peterson, Assistant Professor, Cancer Genetics and Signaling, Fox Chase Cancer Center
Mapping Protein Kinase Networks and Drug Interactions with Protein Microarrays and Predictive Bioinformatics
Steven Pelech, President & CSO, Medicine, Kinexus; Professor, University of British
Developing Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Greg Cuny, Ph.D., Director of Medicinal Chemistry, Laboratory for Drug Discovery in Neurodegeneration (LDDN), Harvard NeuroDiscovery Center
Targeting Protein Kinases in CNS Discovery
D. Martin Watterson, Ph.D., J.G. Searle Professor & Co-Director, Center for Drug Discovery & Chemical Biology, Northwestern University
How the Proteome Acts on the Genome, Causing the Heart to Fail: New Approaches for Therapeutic Intervention
Thomas Vondriska, Ph.D., Assistant Professor, Anesthesiology, Medicine & Physiology, UCLA
Talk Title to be Announced
Heidi Hope, Ph.D., Pfizer, Inc. (tentative)
Preliminary List of Topics to be Covered:
Target Identification and Screening Strategies
Designing Selective Inhibitors
ADME Issues
Antibody Approach to Kinase Targets
Strategies to Overcome Resistance Mutations
Structure-Based Design
Target-Ligand Binding
Clinical Trials
Assay Development
Fragment-Binding
Target Validation
Data Analysis
Multiple Kinase Targeting
Novel Therapeutic Targets
Animal Models using Kinases
Kinase Specificity
Non ATP - Competitive Inhibiting
Protein Crystallography of Kinases
Lead Optimization
Please note: There are still a few speaking slots available at this meeting. If you would like to give an oral presentation, please submit a proposal, including the title and brief (3-5 sentences) summary on your recent work in the area. All proposals are subject to review by the scientific advisory board to ensure the overall quality of the conference.
Margit Eder, Ph.D., Conference Director
Phone: 781-972-5478, E-mail: meder@healthtech.com
For sponsorship or exhibiting information, please contact:
Jon Stroup, Manager, Business Development
Phone: 781-972-5483, E-mail: jstroup@healthtech.com